Investor Presentaiton

sanofi PCV21 (SP0202) Phase 2 designed to enable pivotal program Study design 4-dose regimen Months > Safety 2 4 6 7 12 15 13-16 PCV21 Formulation #1 n= 175 PCV21 Formulation #2 Infants 2 Months n= 175 PCV21 Formulation #3 n = 175 62 Vaccines Investor Event PCV13 n = 175 > Immunogenicity - Post-dose 3 IgG geometric mean concentration and seroresponse Post-dose 4 IgG geometric mean concentration => Standard evaluation criteria for pivotal trials and registration > Select formulation for pivotal program

View entire presentation